Shanghai Henlius Biotech, Inc.

Symbol: 2696.HK




Market price today

  • -8.0833

    P/E Ratio

  • 0.0948

    PEG Ratio

  • 6.22B

    MRK Cap

  • 0.00%

    DIV Yield

Shanghai Henlius Biotech, Inc. (2696-HK) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Jun Zhu
Full-time employees:3602
Address:Innov Tower (Capitaland Building)

Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

General Outlook

In simple terms, Shanghai Henlius Biotech, Inc. has 543.495 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.737% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.182%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.216%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.078% return, is a testament to Shanghai Henlius Biotech, Inc.'s adeptness in optimizing resource deployment. Shanghai Henlius Biotech, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.354%. Furthermore, the proficiency of Shanghai Henlius Biotech, Inc. in capital utilization is underscored by a remarkable -0.150% return on capital employed.

Stock Prices

Shanghai Henlius Biotech, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $13.12, while its low point bottomed out at $12.68. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Shanghai Henlius Biotech, Inc.'s stock market.

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of Shanghai Henlius Biotech, Inc. (2696.HK) on the HKSE in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -8.083 in 2023.

What is the ticker symbol of Shanghai Henlius Biotech, Inc. stock?

The ticker symbol of Shanghai Henlius Biotech, Inc. stock is 2696.HK.

What is company IPO date?

IPO date of Shanghai Henlius Biotech, Inc. is 2019-09-25.

What is company current share price?

Current share price is 11.440 HKD.

What is stock market cap today?

The market cap of stock today is 6217582251.000.

What is PEG ratio in 2023?

The current 0.095 is 0.095 in 2023.

What is the number of employees in 2023?

In 2023 the company has 3602.